Free Trial

Trevena (TRVN) Competitors

Trevena logo
$0.91 -0.02 (-2.28%)
As of 07/17/2025 10:49 AM Eastern

TRVN vs. ONVO, GLMD, CERO, GENE, LIPO, ENVB, SXTP, UBX, PBM, and ARAV

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Organovo (ONVO), Galmed Pharmaceuticals (GLMD), CERo Therapeutics (CERO), Genetic Technologies (GENE), Lipella Pharmaceuticals (LIPO), Enveric Biosciences (ENVB), 60 Degrees Pharmaceuticals (SXTP), UNITY Biotechnology (UBX), Psyence Biomedical (PBM), and Aravive (ARAV). These companies are all part of the "pharmaceutical products" industry.

Trevena vs. Its Competitors

Trevena (NASDAQ:TRVN) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Trevena has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. Trevena's return on equity of 0.00% beat Organovo's return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Organovo -10,151.64%-346.26%-187.53%

Trevena presently has a consensus price target of $5.00, suggesting a potential upside of 449.45%. Given Trevena's stronger consensus rating and higher possible upside, equities research analysts plainly believe Trevena is more favorable than Organovo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organovo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Trevena's average media sentiment score of 0.00 equaled Organovo'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Organovo Neutral

13.6% of Trevena shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 3.7% of Organovo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organovo has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K1.97-$40.29M-$47.04-0.02
Organovo$122K0.00-$14.67M-$10.20N/A

Trevena has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Summary

Trevena beats Organovo on 8 of the 12 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$873K$816.22M$5.54B$9.41B
Dividend YieldN/A4.84%3.75%4.03%
P/E Ratio-0.021.2021.0120.09
Price / Sales1.9725.49433.8199.01
Price / CashN/A19.5636.1658.27
Price / Book-0.086.878.125.65
Net Income-$40.29M-$4.17M$3.25B$257.91M
7 Day Performance-2.69%0.03%0.97%2.09%
1 Month Performance-20.18%2.12%7.36%11.13%
1 Year Performance-85.24%2.14%31.31%18.40%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
1.2006 of 5 stars
$0.91
-2.3%
$5.00
+449.5%
-85.0%$873K$443K-0.0240Positive News
Gap Down
ONVO
Organovo
N/AN/AN/AN/A$3.47M$122K-2.4020Gap Up
GLMD
Galmed Pharmaceuticals
1.2597 of 5 stars
$2.09
+8.0%
N/A-39.1%$3.45MN/A-0.1320
CERO
CERo Therapeutics
3.9213 of 5 stars
$8.67
-0.6%
$45.00
+419.0%
-97.9%$3.38MN/A0.008
GENE
Genetic Technologies
N/A$0.77
flat
N/AN/A$3.37M$7.66M0.0050News Coverage
High Trading Volume
LIPO
Lipella Pharmaceuticals
1.6549 of 5 stars
$0.75
-9.5%
N/A-79.4%$3.36M$536.36K-0.184
ENVB
Enveric Biosciences
2.5651 of 5 stars
$1.34
+2.3%
$10.00
+646.3%
-83.4%$3.31MN/A-0.0320
SXTP
60 Degrees Pharmaceuticals
2.7385 of 5 stars
$2.16
-14.3%
$7.00
+224.1%
+29.1%$3.18M$665.45K-0.043High Trading Volume
UBX
UNITY Biotechnology
4.5241 of 5 stars
$0.18
-40.4%
$3.75
+1,995.0%
-88.1%$3.08MN/A-0.1160Positive News
Upcoming Earnings
Gap Down
High Trading Volume
PBM
Psyence Biomedical
0.9915 of 5 stars
$5.36
+4.3%
N/A-97.8%$3.06MN/A0.00N/APositive News
Gap Up
ARAV
Aravive
N/A$0.04
flat
N/AN/A$2.95M$9.14M0.0020High Trading Volume

Related Companies and Tools


This page (NASDAQ:TRVN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners